An HIV/VL patient’s long road to better treatment

Man sitting on a bed in a hospital

Nigatu Abebe from Ethiopia sits on a bed in the Leishmaniasis Research and Treatment Centre (LRTC) at the University of Gondar in Ethiopia. He looks very frail and has been battling against visceral leishmaniasis (VL), also known as kala-azar, and HIV for 11 years.

Combination therapy found to be more effective in treating patients with leishmaniasis and HIV

Geneva/Nairobi – 17 January 2019

The results of clinical trials conducted in Ethiopia by DNDi, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options. The results were published today in PLOS Neglected Tropical Diseases.

Drug discovery for kinetoplastid diseases: future directions

by Rao S, Barrett M, Dranoff G, Farady C, Gimpelewicz C, Hailu A, Jones C, Kelly J, Lazdins-Helds J, Maeser P, Mengel J, Mottram J, Mowbray C, Sacks D, Scott P, Späth G, Tarleton RL, Spector J, Diagana T.

American Chemical Society Infectious Diseases, December 2018

ASTMH 2018

67th Annual Meeting

28 October – 1 November 2018
New Orleans, USA

  • Nathalie Strub-Wourgaft, NTD Director – presentation on fexinidazole in a symposium on sleeping sickness elimination
  • Colin Forsyth, Chagas Epidemiologist, Sergio Sosa Estani, Head of Chagas Clinical Programme, Eric Chatelain, Head of Drug Discovery Programme – symposium on screening and diagnosis of Chagas disease
  • Poster and oral presentations on sleeping sickness, visceral leishmaniasis, Chagas, onchocerciasis, and mycetoma

New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier

Nairobi/Khartoum – 12 September 2018

Trial to take place in Sudan, which has the world’s highest rates of this highly stigmatizing disease
A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan. The objective of this clinical trial, which is being conducted by the DNDand the Institute for Endemic Diseases at the University of Khartoum, is to shorten the length of hospitalization for PKDL, and deliver a treatment that is safer to use and easier to administer.